Bengaluru, Jan. 8 -- specialising in manufacturing generic injectable pharmaceuticals, focusing on complex sterile injectables, oncology, and ophthalmics, offering products in vials, pre-filled syringes, and more, are in focus as it expands its portfolio with a USFDA nod for Olopatadine Eye Drops.
With a market capitalization of Rs. 28,492.98 Crores on Thursday, the shares of Gland Pharma Ltd jumped upto 5.1 percent, reaching a high of Rs. 1795.85 compared to its previous closing price of Rs. 1708.50.
What Happened
Gland Pharma Ltd, engaged in manufacturing generic injectable pharmaceuticals, focusing on complex sterile injectables, oncology, and ophthalmics, offering products in vials, pre-filled syringes, and more, has informed that ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.